Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko
Merck KGaA said Tuesday that the drug it licensed from a China-based biotech has secured FDA approval for rare noncancerous tumors that impact the joints. The German conglomerate got the
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.